WH-4-023 is primarily used in research settings as a selective inhibitor of protein-protein interactions, particularly targeting pathways involved in cancer cell signaling. It has shown potential in disrupting the binding between specific oncogenic proteins, thereby inhibiting tumor growth and promoting apoptosis in malignant cells. Its application is valuable in early-stage drug discovery for oncology, where it serves as a tool compound to validate therapeutic targets. Due to its specificity, WH-4-023 is also employed in cellular and biochemical assays to study signaling mechanisms in immune and inflammatory responses. Currently, it remains under investigation and is not approved for clinical use.